Immune Analysis of Radium-223 in Patients With Metastatic Prostate Cancer.

ABSTRACT:

Background

Radium223 (Ra223) delivers high-energy radiation to osteoblastic metastasis of prostate cancer, resulting in irreparable double-stranded DNA damage. The effects of Ra223 on CD8+ T cell subsets in patients with prostate cancer is unknown.

Patients and methods

Fifteen men with metastatic prostate cancer with clinical indication for Ra223 without any autoimmune or immune deficiency conditions were enrolled. Patients received a course of Ra223 50 kBq/kg. Concurrent use of prednisone ≤ 10 mg a day was allowed. Peripheral blood samples were collected before and 3 to 4 weeks after the first dose of Ra223 50 kBq/kg. Peripheral blood mononuclear cells were purified and analyzed for the phenotypic and functional characteristics of CD8⁺ T cells using flow cytometr

SUBMITTER: Kim JW 

PROVIDER: S-EPMC5878980 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature